Cardax Inc
OTC:CDXI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cardax Inc
Net Income
Cardax Inc
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cardax Inc
OTC:CDXI
|
Net Income
-$5.1m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income
$26.8B
|
CAGR 3-Years
28%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income
$7.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income
$7.8B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
32%
|
CAGR 10-Years
15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income
$20.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
27%
|
CAGR 10-Years
24%
|
|
Cardax Inc
Glance View
Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The company is headquartered in Honolulu, Hawaii and currently employs 10 full-time employees. The company went IPO on 2012-01-30. The firm has a commercial business unit that markets dietary supplements for inflammatory health. The firm's product platform consists of CDX-101, astaxanthin pharmaceutical candidate, that is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the Company’s zeaxanthin pharmaceutical candidate, is being developed for macular degeneration. Its pharmaceutical candidates are in pre-clinical development, including the planning of investigational new drug (IND) enabling studies. ZanthoSyn is a physician recommended astaxanthin dietary supplement for inflammatory health. The firm sells ZanthoSyn primarily through wholesale and e-commerce channels.
See Also
What is Cardax Inc's Net Income?
Net Income
-5.1m
USD
Based on the financial report for Dec 31, 2020, Cardax Inc's Net Income amounts to -5.1m USD.
What is Cardax Inc's Net Income growth rate?
Net Income CAGR 5Y
-3%
Over the last year, the Net Income growth was 1%. The average annual Net Income growth rates for Cardax Inc have been -37% over the past three years , -3% over the past five years .
